pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC
Cartesian Therapeutics
Cartesian Therapeutics patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 7495 New Horizon Way, Frederick, Maryland 21703, US
- Founded
- 2016
- Employees
- 89
- Programs
- 12
- Drugs
- 4
- Patents
- 4
Cartesian Therapeutics patents
4 pharmaceutical patents indexed for Cartesian Therapeutics. 0 expire within 24 months.
Cartesian Therapeutics has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12194078
Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
granted -
US 11999773
Anti-BCMA chimeric antigen receptors
granted -
US 11220535
Anti-BCMA chimeric antigen receptors
granted -
US 10934337
Anti-BCMA chimeric antigen receptors
granted
Frequently asked questions
How many patents does Cartesian Therapeutics have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Cartesian Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.